Positive News SentimentPositive NewsNASDAQ:MXCT MaxCyte (MXCT) Stock Forecast, Price & News $3.02 -0.10 (-3.21%) (As of 10/2/2023 ET) Add Compare Share Share Today's Range$3.01▼$3.1550-Day Range$3.02▼$4.7852-Week Range$2.99▼$7.50Volume385,497 shsAverage Volume495,171 shsMarket Capitalization$312.69 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media MaxCyte MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside247.7% Upside$10.50 Price TargetShort InterestBearish2.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$120,981 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.37) to ($0.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.03 out of 5 starsMedical Sector600th out of 969 stocksCommercial Physical Research Industry11th out of 14 stocks 3.5 Analyst's Opinion Consensus RatingMaxCyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, MaxCyte has a forecasted upside of 247.7% from its current price of $3.02.Amount of Analyst CoverageMaxCyte has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.30% of the float of MaxCyte has been sold short.Short Interest Ratio / Days to CoverMaxCyte has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in MaxCyte has recently increased by 7.14%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMaxCyte does not currently pay a dividend.Dividend GrowthMaxCyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MXCT. Previous Next 3.3 News and Social Media Coverage News SentimentMaxCyte has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for MaxCyte this week, compared to 0 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MaxCyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $120,981.00 in company stock.Percentage Held by InsidersOnly 6.00% of the stock of MaxCyte is held by insiders.Percentage Held by Institutions62.25% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MaxCyte are expected to decrease in the coming year, from ($0.37) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MaxCyte is -9.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MaxCyte is -9.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaxCyte has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MaxCyte (NASDAQ:MXCT) StockMaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.Read More MXCT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MXCT Stock News HeadlinesSeptember 6, 2023 | finanznachrichten.deMaxCyte, Inc: MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of BioprocessingSeptember 6, 2023 | finance.yahoo.comMaxCyte Appoints Ali Soleymannezhad as Executive Vice President of BioprocessingOctober 2, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 5, 2023 | finance.yahoo.comMaxCyte to Participate in Baird Global Healthcare ConferenceAugust 11, 2023 | finanznachrichten.deMaxCyte, Inc.: MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 GuidanceJuly 10, 2023 | finanznachrichten.deMaxCyte, Inc: MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular TherapiesJuly 8, 2023 | finance.yahoo.comMaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 77% of the companyJune 9, 2023 | seekingalpha.comPRTS, CRBU and NDLS are among after hour moversOctober 2, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 30, 2023 | msn.comMaxCyte: Engineering The Next Biotech WaveMay 18, 2023 | finanznachrichten.deMaxCyte, Inc: MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 GuidanceMay 12, 2023 | msn.comRecap: MaxCyte Q1 EarningsMay 11, 2023 | seekingalpha.comMaxCyte, Inc. 2023 Q1 - Results - Earnings Call PresentationMay 10, 2023 | finance.yahoo.comMaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue EstimatesMay 10, 2023 | finance.yahoo.comMaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 GuidanceMay 4, 2023 | finance.yahoo.comMaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell PlatformApril 12, 2023 | finance.yahoo.comMaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023April 6, 2023 | finance.yahoo.comThe three-year returns have been strong for MaxCyte (LON:MXCT) shareholders despite underlying losses increasingMarch 17, 2023 | finance.yahoo.comMaxCyte Full Year 2022 Earnings: US$0.23 loss per share (vs US$0.21 loss in FY 2021)March 15, 2023 | msn.comMaxCyte GAAP EPS of -$0.05 beats by $0.02, revenue of $10.88M misses by $2.25MMarch 15, 2023 | finance.yahoo.comMaxCyte Reports Fourth Quarter and Full Year 2022 Financial ResultsFebruary 1, 2023 | finance.yahoo.comMaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor ConferencesJanuary 3, 2023 | finance.yahoo.comMaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy ProgramsDecember 8, 2022 | finance.yahoo.comMaxCyte, Inc. (MXCT) Moves to Buy: Rationale Behind the UpgradeDecember 6, 2022 | seekingalpha.comMaxCyte Is Poised For A Strong ReboundDecember 5, 2022 | markets.businessinsider.comMaxCyte, Curamys In Strategic Platform License DealNovember 13, 2022 | fool.comMaxCyte, Inc. (NASDAQ: MXCT)See More Headlines Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address MXCT Company Calendar Last Earnings8/09/2023Today10/02/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MXCT CUSIPN/A CIK1287098 Webmaxcyte.com Phone301-944-1700Fax301-944-1703Employees125Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.50 High Stock Price Forecast$12.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+236.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,570,000.00 Net Margins-80.22% Pretax Margin-80.22% Return on Equity-13.09% Return on Assets-11.60% Debt Debt-to-Equity RatioN/A Current Ratio17.92 Quick Ratio17.08 Sales & Book Value Annual Sales$44.26 million Price / Sales7.30 Cash FlowN/A Price / Cash FlowN/A Book Value$2.47 per share Price / Book1.26Miscellaneous Outstanding Shares103,540,000Free Float97,325,000Market Cap$323.04 million OptionableOptionable Beta0.84 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Douglas Arthur Doerfler (Age 67)Founder, Pres, CEO & Exec. Director Comp: $1.2MDr. Cenk Sumen Ph.D. (Age 49)Chief Scientific Officer Comp: $575.6kMr. Maher Masoud (Age 48)Exec. VP, Gen. Counsel & Sec. Comp: $612.07kMr. Douglas J. Swirsky CFA (Age 54)CPA, Chief Financial Officer Mr. Ronald Evan Holtz CPA (Age 65)Ph.D., Exec. VP of Admin. Mr. Sean MenarguezDirector of Investor RelationsMr. Thomas Michael Ross (Age 62)Exec. VP of Global Sales & Marketing Dr. J. Stark Thompson Ph.D. (Age 81)Consultant Dr. James Brady Ph.D.Sr. VP of Technical Applications & Customer SupportDr. Sarah Haecker Meeks Ph.D.Sr. VP of Bus. Devel.More ExecutivesKey CompetitorsAbsciNASDAQ:ABSIData Knights AcquisitionNASDAQ:DKDCATerns PharmaceuticalsNASDAQ:TERNCVRxNASDAQ:CVRXNature's Sunshine ProductsNASDAQ:NATRView All CompetitorsInsiders & InstitutionsBarclays PLCSold 42,954 shares on 9/21/2023Ownership: 0.034%John Joseph JohnstonSold 2,841 sharesTotal: $10,511.70 ($3.70/share)John Joseph JohnstonSold 100 sharesTotal: $370.00 ($3.70/share)Alberta Investment Management CorpBought 176,812 shares on 8/24/2023Ownership: 0.171%California State Teachers Retirement SystemBought 10,493 shares on 8/21/2023Ownership: 0.102%View All Insider TransactionsView All Institutional Transactions MXCT Stock - Frequently Asked Questions Should I buy or sell MaxCyte stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MXCT shares. View MXCT analyst ratings or view top-rated stocks. What is MaxCyte's stock price forecast for 2023? 1 analysts have issued 1 year target prices for MaxCyte's stock. Their MXCT share price forecasts range from $9.00 to $12.00. On average, they expect the company's stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 236.5% from the stock's current price. View analysts price targets for MXCT or view top-rated stocks among Wall Street analysts. How have MXCT shares performed in 2023? MaxCyte's stock was trading at $5.46 at the beginning of 2023. Since then, MXCT shares have decreased by 42.9% and is now trading at $3.12. View the best growth stocks for 2023 here. When is MaxCyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our MXCT earnings forecast. How were MaxCyte's earnings last quarter? MaxCyte, Inc. (NASDAQ:MXCT) issued its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). The firm earned $9.04 million during the quarter, compared to analyst estimates of $11 million. MaxCyte had a negative trailing twelve-month return on equity of 13.09% and a negative net margin of 80.22%. When did MaxCyte IPO? (MXCT) raised $150 million in an IPO on Friday, July 30th 2021. The company issued 12,000,000 shares at a price of $11.50-$13.50 per share. What is MaxCyte's stock symbol? MaxCyte trades on the NASDAQ under the ticker symbol "MXCT." How do I buy shares of MaxCyte? Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MaxCyte's stock price today? One share of MXCT stock can currently be purchased for approximately $3.12. How much money does MaxCyte make? MaxCyte (NASDAQ:MXCT) has a market capitalization of $323.04 million and generates $44.26 million in revenue each year. The company earns $-23,570,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. How many employees does MaxCyte have? The company employs 125 workers across the globe. How can I contact MaxCyte? MaxCyte's mailing address is 22 FIRSTFIELD ROAD SUITE 110, GAITHERSBURG MD, 20878. The official website for the company is maxcyte.com. The company can be reached via phone at 301-944-1700, via email at ir@maxcyte.com, or via fax at 301-944-1703. This page (NASDAQ:MXCT) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.